N-butyllithocholamide | 1126486-70-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: N-butyllithocholamide
• 英文别名: N-n-butyl-3α-hydroxy-5β-cholan-24-amide；(4R)-N-butyl-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanamide
• CAS: 1126486-70-1
• 化学式: C₂₈H₄₉NO₂
• 分子量: 431.703
• InChiKey: KWMYCWAXIFBMCT-WQKHHYSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-butyllithocholamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 24-n-butylamino-5β-cholan-3α-ol
  参考文献：
  名称：

  石胆酸新型酰胺键二聚体的合成

  摘要：

  描述了在温和条件下有效合成石胆酸酰胺和酰胺连接的二聚体。新的邻、间和对苯二胺衍生的石胆酸二聚体是通过活化胆汁酸的羧基作为酸与氯甲酸乙酯反应产生的混合酸酐来合成的。石胆酸酰胺的还原得到相应的 24-氨基-5β-胆烷衍生物。所有化合物均通过 IR、1H 和 13C NMR 和质谱进行表征。

  DOI：

  10.3184/030823408x318325
• 作为产物：
  描述：

  石胆酸 在 三乙胺 作用下， 反应 20.5h， 生成 N-butyllithocholamide
  参考文献：
  名称：

  胆汁酸烷基酰胺的超分子凝胶化特性的系统调节

  摘要：

  详细研究了九种基于胆酸烷基酰胺的低分子量胶凝剂（LMWG）的自组装性能。基于该结果，尽管脂族侧链的性质也调节了凝胶化能力，但是连接至甾族骨架的羟基数目在凝胶化中起着重要作用。在研究的50种凝胶体系中，有35种基于石胆酸，而15种基于胆酸衍生物。脱氧胆酸衍生物没有形成任何凝胶。凝胶化主要发生在芳族溶剂中，并且凝胶表现出典型的纤维或球形形态。在13在结晶材料和相应的湿有机凝胶上测得的C交叉极化魔角旋转（CPMAS）NMR光谱是相似的，这表明两种材料中发现的化学环境（即分子间相互作用）相似。研究的所有九种胆酸酰胺衍生物的单晶X射线结构揭示了固态中非常相似的分子构象，并洞悉了凝胶态下可能的分子间相互作用。

  DOI：

  10.1002/chem.201803151

文献信息

• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20150119345A1

  公开（公告）日：2015-04-30

  Provided herein are methods for treating or preventing gastrointestinal and/or liver infections utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists. Also provided herein are methods for increasing the levels of an enteroendocrine peptide or hormone in an individual suffering from a gastrointestinal infection or liver infection utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists.

  本文提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂治疗或预防胃肠和/或肝感染的方法。本文还提供了利用胆汁酸转运抑制剂和/或肠内分泌肽增强剂和/或FXR激动剂增加患有胃肠感染或肝感染的个体体内肠内分泌肽或激素水平的方法。
• Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20130108573A1

  公开（公告）日：2013-05-02

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了一种治疗或改善高胆固醇血症或胆汁淤积性肝病的方法，即通过向需要的个体施用治疗有效量的顶端钠依赖性胆酸转运蛋白抑制剂（ASBTI）或其药用可接受盐。还提供了一种治疗或改善肝病、降低血清胆酸或肝内胆酸水平、治疗或改善瘙痒、降低肝酶或减少胆红素的方法，即通过向需要的个体施用治疗有效量的ASBTI或其药用可接受盐。
• Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20130109671A1

  公开（公告）日：2013-05-02

  Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了一种通过非系统性给予需要治疗或改善儿童胆汁淤积性肝病的个体治疗的方法，该方法包括给予含有顶端钠依赖性胆酸转运体抑制剂（ASBTI）或其药学上可接受的盐的儿科制剂的治疗有效量。此外，还提供了一种治疗或改善儿童肝病、降低血清胆酸或肝胆酸水平、治疗或改善瘙痒、降低肝酶或减少胆红素的方法，该方法包括给予含有ASBTI或其药学上可接受的盐的儿科制剂的治疗有效量。
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20140323412A1

  公开（公告）日：2014-10-30

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供的是治疗或改善高胆固醇血症或胆汁淤积性肝病的方法，通过向需要治疗的个体施用治疗有效量的顶端钠依赖性胆酸转运体抑制剂（ASBTI）或其药学上可接受的盐。还提供了治疗或改善肝病、降低血清胆汁酸或肝胆汁酸水平、治疗或改善瘙痒症、降低肝酶或胆红素的方法，通过向需要治疗的个体施用治疗有效量的ASBTI或其药学上可接受的盐。
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
  申请人：Lumena Pharmaceuticals, Inc.

  公开号：US20140243281A1

  公开（公告）日：2014-08-28

  Provided herein are pediatric dosage forms for use in the treatment of a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of the pediatric dosage form comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are said pediatric dosage form for use in the treatment of a pediatric liver disease, for use in decreasing the levels of serum bile acids or hepatic bile acids, for use in the treatment of pruritis, for use in reducing liver enzymes or bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了用于治疗儿童胆汁淤积性肝病的儿童剂型，通过非系统性给予需要治疗的个体含有顶端钠依赖性胆酸转运体抑制剂（ASBTI）或其药学上可接受的盐的治疗有效量的儿童剂型。还提供了该儿童剂型用于治疗儿童肝病，用于降低血清胆酸或肝胆酸水平，用于治疗瘙痒症，用于减少肝酶或胆红素的儿童制剂，通过非系统性给予需要治疗的个体含有ASBTI或其药学上可接受的盐的治疗有效量。